First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [21] Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study
    Wu, Yili
    Ye, Jiankui
    Shao, Zhuowei
    Rossi, Antonio
    Chen, Yu
    Li, You
    Wu, Shibo
    JOURNAL OF THORACIC DISEASE, 2024, 16 (08) : 5348 - 5360
  • [22] Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
    Cheng, Ying
    Fan, Yun
    Zhao, Yanqiu
    Huang, Dingzhi
    Li, Xingya
    Zhang, Peng
    Kang, Mafei
    Yang, Nong
    Zhong, Diansheng
    Wang, Zhen
    Yu, Yan
    Zhang, Yu
    Zhao, Jun
    Qin, Tai
    Chen, Chenqi
    Leaw, Shiangjiin
    Zheng, Wenjuan
    Song, Yong
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : 1073 - 1085
  • [23] A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer
    Li, Shujun
    Liang, Yahai
    Wu, Yanxia
    Huang, Zhong
    Lin, Yanming
    Yang, Zhixiong
    Chen, Hualin
    Wu, Aibing
    JOURNAL OF BUON, 2020, 25 (03): : 1490 - 1496
  • [24] A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer
    Kalemkerian, GP
    Ali, MA
    Luthra, K
    Wozniak, AJ
    Valdivieso, M
    Kraut, MJ
    CANCER INVESTIGATION, 2001, 19 (03) : 234 - 238
  • [25] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
    Zhou, Fei
    Zhao, Wencheng
    Gong, Xiaomei
    Ren, Shengxiang
    Su, Chunxia
    Jiang, Tao
    Zhou, Caicun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [26] Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial
    Reguart Aransay, N.
    Victoria, I.
    Marti, J. L.
    Carcereny, E.
    Arasanz, H.
    Domine, M.
    Fernandez, N.
    Sala, M. A.
    Marin, E.
    Sanfeliu, E.
    Arcocha, A.
    Martinez, D.
    Reyes, R.
    Navarro, A.
    Barba, A.
    Garcia-Campelo, R.
    Giner, J.
    Blasco, A.
    Sais, E.
    Gutierrez, V.
    Marse, R.
    Martin, P.
    Zugazagoita, J.
    Salinas, B.
    Cobo, S.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S375 - S375
  • [27] Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
    Lang, Wenwang
    Ai, Qi
    He, Yulong
    Pan, Yufei
    Jiang, Qinling
    Ouyang, Ming
    Sun, Tianshou
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (06) : 1536 - 1545
  • [28] Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab
    Isla, D.
    Arriola, E.
    Garcia Campelo, M. R.
    Marti, C.
    Diz Tain, P.
    Moreno Vega, A. L.
    Piqueras, M. L-B.
    Leon, L.
    Gutierrez Calderon, V.
    Oramas Rodriguez, J. M.
    Majem, M.
    Sanchez-Hernandez, A.
    Aguado de la Rosa, C.
    Alvarez Cabellos, R.
    Marti-Ciriquian, J. L.
    Moreno Paul, A.
    Gonzalez Cordero, M.
    Callejo Mellen, A.
    Baez, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S98 - S99
  • [29] Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial☆
    Lee, Siow Ming
    Hewish, Madeleine
    Ahmed, Samreen
    Papadatos-Pastos, Dionysis
    Karapanagiotou, Eleni
    Blackhall, Fiona
    Ford, Amy
    Young, Robin
    Garcia, Angel
    Arora, Arvind
    Hollingdale, Abigail
    Ahmad, Tanya
    Forster, Martin
    Greystoke, Alastair
    Bremner, Fion
    Rudd, Robin
    Farrelly, Laura
    Vaja, Simran
    Hackshaw, Allan
    EUROPEAN JOURNAL OF CANCER, 2025, 215
  • [30] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
12345